-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis' Coartem Baby Wins Approval in 16 Countries

PUBT·11/10/2026 13:02:18
Listen to the news
Novartis' Coartem Baby Wins Approval in 16 Countries
  • Novartis received priority review for next-generation antimalarial KLU156 (ganaplacide/lumefantrine), submitted to Swissmedic and the U.S. FDA.
  • Coartem Baby, its malaria treatment for newborns and young infants, has secured approval in 16 countries.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100800OMX_____CNEWS_EN_GNW1001302648_en) on November 10, 2026, and is solely responsible for the information contained therein.